Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals, Inc. (OLMA)
:OLMA
OLMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.86 - $16.62
Previous CloseN/A
Volume1.27M
Average Volume (3M)1.09M
Market Cap
$335.52M
Enterprise Value$585.50K
Total Cash (Recent Filing)$33.72M
Total Debt (Recent Filing)$2.21M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
May 13, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding68,333,060
10 Day Avg. Volume840,975
30 Day Avg. Volume1,089,108
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.00Price Target Upside470.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Olema Pharmaceuticals News
See All OLMA News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsOlema presented updated Phase II data where the combo led to an impressive 13.1 month mPFS in prior CDK4/6i patients.
Drug DevelopmentOlema Pharmaceuticals has promising development opportunities with their complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), palazestrant (OP-1250), in the advanced/metastatic ER+ breast cancer treatment landscape.
Market PotentialThe stock price of Olema Pharmaceuticals is currently not reflecting the potential benefits in ESR1 wild-type patients or the first-line treatment opportunity, suggesting significant upside if these benefits are realized.
Bears Say
Competitor TrialsRecent updates indicate that another oral SERD did not meaningfully improve progression-free survival among ESR1 Wild Type patients, following prior negative results in this group from other companies.
Market SentimentThe short interest percentage of float for Olema Pharmaceuticals stands at 11.9%, indicating a significant portion of investors are betting against the stock.
Stock Price MovementThe decline in Olema's share price was not a response to OLMA's Phase II update, but instead the disappointing data from Eli Lilly's Phase III EMBER-3 trial.
---
Ownership Overview
21.51% Insiders
9.06% Mutual Funds
0.35% Other Institutional Investors
61.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OLMA FAQ
What was Olema Pharmaceuticals, Inc.’s price range in the past 12 months?
Olema Pharmaceuticals, Inc. lowest stock price was $2.86 and its highest was $16.62 in the past 12 months.
What is Olema Pharmaceuticals, Inc.’s market cap?
Olema Pharmaceuticals, Inc.’s market cap is $335.52M.
When is Olema Pharmaceuticals, Inc.’s upcoming earnings report date?
Olema Pharmaceuticals, Inc.’s upcoming earnings report date is May 13, 2025 which is in 15 days.
How were Olema Pharmaceuticals, Inc.’s earnings last quarter?
Olema Pharmaceuticals, Inc. released its earnings results on Mar 18, 2025. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.636 by $0.126.
Is Olema Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Olema Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Olema Pharmaceuticals, Inc. pay dividends?
Olema Pharmaceuticals, Inc. does not currently pay dividends.
What is Olema Pharmaceuticals, Inc.’s EPS estimate?
Olema Pharmaceuticals, Inc.’s EPS estimate is -0.51.
How many shares outstanding does Olema Pharmaceuticals, Inc. have?
Olema Pharmaceuticals, Inc. has 68,333,060 shares outstanding.
What happened to Olema Pharmaceuticals, Inc.’s price movement after its last earnings report?
Olema Pharmaceuticals, Inc. reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.636. Following the earnings report the stock price went down -0.725%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in OLMA
---
Olema Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.00 (470.26% Upside)
$28.00 (470.26% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 237.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.05%
12-Months-Change
Fundamentals
Return on Equity
-39.07%
Trailing 12-Months
Asset Growth
62.84%
Trailing 12-Months
Company Description
Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
---
OLMA Stock 12 Month Forecast
Average Price Target
$28.00
▲(470.26% Upside)
Technical Analysis
aTyr Pharma
―
Taysha Gene Therapies
―
Monte Rosa Therapeutics
―
2seventy bio
―
Septerna, Inc.
―
Best Analysts Covering OLMA
1 Year
1 Year Success Rate
9/21 ratings generated profit
1 Year Average Return
+53.67%
reiterated a buy rating last month
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +53.67% per trade.
---